Clinical bottom line
Immune checkpoint inhibitors (ICIs), increasingly used in oncology, can trigger a spectrum of rare autoimmune syndromes affecting endocrine, neurologic, respiratory, and neuromuscular systems. These immune-related adverse events (irAEs) often present abruptly and may mimic idiopathic autoimmune diseases but require distinct recognition and management strategies. Early identification and multidisciplinary care are critical to mitigate morbidity. While corticosteroids remain the mainstay of treatment, tailored immunosuppression and supportive therapies depend on the specific syndrome. Current evidence is largely retrospective and case-based, underscoring the need for heightened clinical vigilance and further prospective studies.
What the evidence shows
ICI-induced autoimmune syndromes encompass diverse clinical phenotypes, with autoimmune type 1 diabetes mellitus (T1DM), myasthenia gravis (MG), myositis, myocarditis, autoimmune encephalitis, meningitis, tracheitis, and other rare manifestations reported.
- Autoimmune T1DM induced by ICIs typically presents with abrupt onset insulin deficiency and diabetic ketoacidosis. Banerji et al. (2026) analyzed a multicenter cohort revealing that most patients required permanent insulin therapy, with variable recovery of beta-cell function. Early recognition is essential given the life-threatening potential of diabetic ketoacidosis.
- Neurologic irAEs include autoimmune encephalitis and meningitis, often presenting with seizures, cognitive decline, or focal neurologic deficits. Shin et al. (2019) described autoimmune meningoencephalitis cases linked to ICIs, highlighting the need for prompt immunotherapy. Jia et al. (2023) reported focal seizures secondary to ICI-induced autoimmune encephalitis, emphasizing diagnostic challenges.
- The “triple M syndrome” of MG, myositis, and myocarditis represents a severe neuromuscular irAE cluster. Watts et al. (2024) reviewed management strategies, noting high morbidity and mortality without early immunosuppression and cardiac monitoring.
- Rare respiratory irAEs such as ICI-induced tracheitis have been documented (Agrawal et al., 2023), expanding the spectrum of potential autoimmune toxicities.
- Mechanistically, dysregulation of immune checkpoints disrupts self-tolerance, unleashing autoreactive T cells (Tayebi et al., 2026). This underpins the diverse autoimmune phenotypes observed.
Collectively, these reports underscore that ICI-induced autoimmune syndromes can affect multiple organ systems, often requiring urgent intervention and long-term management.
Caveats and uncertainty
The evidence base is predominantly retrospective, observational, and derived from small cohorts or case reports, limiting generalizability. Incidence rates of specific autoimmune syndromes vary widely due to underreporting and heterogeneous diagnostic criteria. The natural history and long-term outcomes remain incompletely characterized, particularly regarding potential reversibility of autoimmune damage.
Optimal immunosuppressive regimens beyond corticosteroids are not well defined, and balancing cancer control with autoimmune toxicity management is challenging. Biomarkers predictive of risk or early detection are lacking, complicating preemptive strategies.
Furthermore, the interplay between ICI type, cancer subtype, and patient-specific factors influencing autoimmune risk is not fully elucidated. There is also uncertainty about the safety of ICI rechallenge after autoimmune irAEs.
How this may change practice
Clinicians treating patients with ICIs should maintain a high index of suspicion for rare autoimmune syndromes presenting with atypical symptoms. Early multidisciplinary involvement—including endocrinology, neurology, cardiology, and pulmonology—is advisable for diagnosis and management.
Routine baseline and periodic monitoring of relevant organ function (e.g., blood glucose, cardiac enzymes, neurologic assessment) may facilitate earlier detection. Prompt initiation of immunosuppressive therapy tailored to the specific autoimmune syndrome can improve outcomes.
Patient education regarding potential autoimmune symptoms is essential to reduce diagnostic delay. Given the complexity of balancing cancer therapy and autoimmune toxicity, individualized risk-benefit assessment and shared decision-making are paramount.
Future research should focus on prospective registries, biomarker development, and clinical trials to optimize management algorithms for these rare but serious irAEs.